Site Map   |  Contact Us  |  Search
TNKase

TNKase Dosing and Administration
Investigate the Molecule
Clinical Data
Publications and Resources
Relevant Links
Product Return and Replacement
Prescribing Information
 LyticExperience Website

  

   


As the only lytic delivered over just one 5-second bolus for the treatment of acute myocardial infarction (AMI), TNKase® (Tenecteplase) enables you to intervene quickly when timing is critical.


 Simple, efficient, 5-second administration

•		 With TNKase, the entire dose is delivered over a single 5-second bolus—no infusion or second bolus is necessary

Assists in compliance with ACC/AHA recommendations1

•		 Convenient administration and ready access aid in initiating therapy within the ACC/AHA guidelines of 30 minutes from door to needle
Indication
For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms.

Important Safety Information
TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information].

The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately.

In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information].

Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown.

Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered.

Please see full Prescribing Information for additional important safety information.

Reference:
1.  Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120(22):2271-2306.








Please see TNKase full Prescribing Information. TNKase® (Tenecteplase). Activase® (Alteplase, recombinant).
© 2013 Genentech, Inc. All rights reserved. TNK0000729204
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080-4990